Russia is reportedly developing a personalized mRNA cancer vaccine tailored to individual tumors. The hosts argue that such treatments should be classified as gene therapy rather than vaccines, suggesting the "vaccine" label is used primarily to provide pharmaceutical companies with legal indemnification and liability protection.











